ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,062.00
-0.10%
S&P 500
5,303.27
0.12%
US Dollar vs CAD
1.36125
-0.03%
Bitcoin
67,224.92
0.42%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Can Fite BioPharma Ltd (CANF)

  7. Can Fite BioPharma Ltd (CANF) News

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:CANF
DateTimeSourceHeadlineSymbolCompany
05/13/20246:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
05/13/20246:00AMBusiness WireCan-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer StudyAMEX:CANFCan Fite BioPharma Ltd
05/09/20246:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
05/09/20246:00AMBusiness WireCan-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb StudyAMEX:CANFCan Fite BioPharma Ltd
05/06/20246:11AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
05/06/20246:00AMBusiness WireCan-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602AMEX:CANFCan Fite BioPharma Ltd
04/25/20246:00AMBusiness WireLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific JournalAMEX:CANFCan Fite BioPharma Ltd
04/15/20246:00AMBusiness WireCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASHAMEX:CANFCan Fite BioPharma Ltd
04/03/20246:00AMBusiness WireCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH PatientsAMEX:CANFCan Fite BioPharma Ltd
03/28/20246:00AMBusiness WireCan-Fite Reports 2023 Financial Results and Clinical UpdateAMEX:CANFCan Fite BioPharma Ltd
03/11/20246:27AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
03/11/20246:00AMBusiness WireNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe ConferenceAMEX:CANFCan Fite BioPharma Ltd
02/28/20246:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
02/28/20246:00AMBusiness WireCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in CanadaAMEX:CANFCan Fite BioPharma Ltd
02/14/20242:32PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsAMEX:CANFCan Fite BioPharma Ltd
01/30/20246:24AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
01/30/20246:00AMBusiness WireCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer IndicationAMEX:CANFCan Fite BioPharma Ltd
01/29/20246:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
01/29/20246:00AMBusiness WireCan-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis StudyAMEX:CANFCan Fite BioPharma Ltd
01/07/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
12/28/20233:16PMEdgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]AMEX:CANFCan Fite BioPharma Ltd
12/20/20236:09AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
12/20/20236:00AMBusiness WireThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human StudiesAMEX:CANFCan Fite BioPharma Ltd
12/18/20236:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
12/18/20236:00AMBusiness WireCan-Fite Received FDA Positive Response to Psoriasis Pediatric PlanAMEX:CANFCan Fite BioPharma Ltd
12/12/20233:15PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersAMEX:CANFCan Fite BioPharma Ltd
12/04/20236:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
12/04/20236:00AMBusiness WireCan-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical DevelopmentAMEX:CANFCan Fite BioPharma Ltd
11/30/20236:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
11/30/20236:00AMBusiness WireCan-Fite Reports Third Quarter 2023 Financial Results and Clinical UpdateAMEX:CANFCan Fite BioPharma Ltd
 Showing the most relevant articles for your search:AMEX:CANF

Your Recent History

BIT
UI022O
Unicredit
NASDAQ
TLRY
Tilray Brands
EU
9210T
9210T
USOTC
NRTZF
Noritz (PK)
NYSE
HBM.WS
HudBay Minerals Inc.
LSE
2TRV
Wt Eu Travel 2x
AMEX
PIO
BOV
BTAG11
Btg Pactual Credito Agri...
CRTO
ENSUSD
Ethereum Name Service
EU
X325S
X325S
USOTC
NNOKF
NOK (PK)
AQSE
3EML.GB
WisdomTree Multi Asset I...
USOTC
HKMPF
Hikma Pharmaceuticals (PK)
BIT
F19482
Vontobel Financial Produ...
AMEX
ITM
VanEck Intermediate Muni...
USOTC
IPAH
Interpharm (CE)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved